AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00602693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous over 2 hours on Day -6
Study NCT00602693 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on Day -1
Study NCT00602693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg infusion
Description: Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
Study NCT00602693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
Study NCT00419692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
Study NCT03568747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive ventilation
Description: dual-limb circuit NIV were given on maquet servo i apparatus
Study NCT03568747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: oxygen therapy were introduced to the side port of the facemask
Study NCT02474979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBPM-system
Description: The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
Study NCT02474979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study NCT03059784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP-based multifaceted management
Description: Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
Study NCT01157897 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge
Study NCT03433716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Neuromodulation
Description: It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
Study NCT01709279 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose tissue derived stromal cells dosage
Description: intra-coronary administration of autologous adipose tissue derived stroma cells
Study NCT02769884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMPPC algorithm artificial pancreas
Description: An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
Study NCT00195013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine
Description: 10 grams three times a day (orally) for four days and then stop
Study NCT00195013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 grams three times a day (orally) for four days and then stop
Study NCT03418506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMOKELESS TOBACCO AWARENESS PROGRAM
Description: A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
Study NCT00161382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, STD, and pregnancy prevention curriculum
Description: This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits.
Study NCT00161382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard sexual education curriculum
Description: Control curriculum consists of standard sexual education.
Study NCT02227654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abnormal Ovarian Ultrasound
Description: Ultrasound
Study NCT04542850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 5-ALA-Phosphate + SFC (5-ALA + SFC)
Description: Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days
Study NCT03522571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental gingivitis
Description: Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
Study NCT03522571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental gingivitis
Description: Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
Study NCT02448121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cell graft
Description: All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
Study NCT01782508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: a selectively inhibits the KIT protein tyrosine
Study NCT01782508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Study NCT01784666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Study NCT01784666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Study NCT01784666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
Study NCT03763760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT03763760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: An intravenous bolus dose of dexamethasone given prior to surgery.
Study NCT01742780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: EZ-IO Intraosseous Vascular Access System
Study NCT04556344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional skills
Description: 3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
Study NCT04556344 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Short free talk and relaxation
Description: 3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
Study NCT01041261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BariatrX Essentials 360 Treatment
Description: Medical food
Study NCT03257358 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fingolimod
Description: Commercially available 0.5mg hard capsules, taken orally once per day
Study NCT00203385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Depakote up to 2000mg/d
Study NCT02418520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miswak
Description: Oral hygiene with Miswak chewing sticks and normal tooth brush
Study NCT02923154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995
Study NCT02923154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01114737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride
Description: A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
Study NCT01114737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
Study NCT02987608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Up
Description: Smartphone phone app
Study NCT00457392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Study NCT00457392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
Study NCT00457392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Study NCT00457392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo daily by oral capsules in a continuous regimen
Study NCT00686673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing tailored message on disclosing terminal illness
Description: an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
Study NCT04995718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intelligent Physical Exercise Training (IPET)
Description: Wind technicians performed 1-hour weekly individualized physical exercise training during working hours. The specific content of the exercise program was based on the specific job exposure profile, the physical capacity profile and the physical health profile of the employee.
Study NCT01084031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intravenous propofol with sevoflurane inhalation induction
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: Acetaminophen IV (15 mg/kg).
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush
Description: Saline placebo will be infused intraoperatively.
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane for anesthesia induction.
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane for anesthesia induction.
Study NCT01691690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide/Oxygen
Description: Combination of NO2 \& O2 for anesthesia induction.
Study NCT00845104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00845104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00845104 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00845104 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies
Study NCT00388960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 45mg/m\<2> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2> IV days 1, 2, 3 plus cisplatin 60mg/m\<2> day 1 of each 21-day cycle until disease progression.
Study NCT00388960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Amrubicin 40mg/m\<2> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2> IV day 1 plus etoposide 100mg/m\<2> IV day 1 and 200mg/m\<2> orally days 2, 3 or etoposide 100mg/m\<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study NCT00686673 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Providing non-tailored message on pain control
Description: an attention control group that receives non-tailored video and manual on pain control
Study NCT00388960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Amrubicin 40mg/m\<2> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2> IV day 1 plus etoposide 100mg/m\<2> IV day 1 and 200mg/m\<2> orally days 2, 3 or etoposide 100mg/m\<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study NCT02207478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
Study NCT02207478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GS-TBLB-X-ray
Description: A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
Study NCT02207478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GS-TBLB-X-ray
Description: A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
Study NCT00845494 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive behavioral intervention
Description: The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
Study NCT00388960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Cisplatin 75mg/m\<2> IV day 1 plus etoposide 100mg/m\<2> IV day 1 and 200mg/m\<2> orally days 2, 3 or etoposide 100mg/m\<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
Study NCT02439203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010
Study NCT02439203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04624828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT treatment Schedule as for clinical practice: Stereotactic body radiation treatment (SBRT) will be delivered with image guidance (image-guided radiation therapy or IGRT) and in the form of volumetric modulated arc therapy (VMAT).~RT treatment Schedule: SBRT will be delivered in 1 to 6 fractions on bone or lymph node metastases. The dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints.
Study NCT04624828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy (ADT)
Description: ADT as for clinical practice:~* for oligorecurrent patients, ADT will be started at time of polimetastatic progression after SBRT;~* for oligoprogressive patients, ADT will be continued during SBRT and untill polimetastatic progression
Study NCT02946944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil/apixaban
Description: After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
Study NCT02429817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid
Description: 99mTc-DTPA solution placed on the nebulizer reservoir
Study NCT03581071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-143
Study NCT04624828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immune evaluation
Description: We will use the flow cytometer FACSymphony, to analyse multiple immune populations from a limited sample of blood. We will monitor the dynamics of most innate (monocytic and granulocytic cells, Natural killer cells) and adaptive (T cells, B cells) immune subsets in the peripheral blood of PC patients before and after RT. We will deeply characterize CD4+ and CD8+ T cell subpopulations circulating in the patients enrolled in the study. In this attempt our panel will include markers of T cell differentiation and activation, including CD25, CD39, PD-1, CTL4, KLRG1, TIM3. We will analyse neutrophils subpopulations and investigate the functional profile of granulocytes in enrolled patients. Markers such as CD66b, CD24, CD16, MHC-II, LOX1, CD36 and CD62L will be included in our analysis. In conclusion our experimental strategy will result in a comprehensive profiling of the immune landscape in PC patients at single cell level.